Prediction of Prostate Cancer Outcome Using
Raman Molecular Imaging

Prostate cancer has a clinical course which is currently unpredictable. Two cases which appear identical based on biopsy can have very different outcomes. Some cancers are indolent, slow growing and would require little or no intervention, while other cancers require aggressive treatment.

ChemImage’s Raman Molecular Imaging (RMI) approach enables, in some cases, discrimination of samples from patients who go on to develop metastatic disease from those who do not.

Why Use RMI for this Application?

• There are no established methods for discrimination between prostate cancer patients
  who will go on to develop metastasis from those who will not.
• The distinction is important because different approaches to treatment can be chosen
  based on how aggressive the disease is.
• RMI has been shown to discriminate these two sub-types of prostate cancer in early
  studies with the Mayo Clinic.
  

Raman molecular images are acquired from tissue samples illuminated by a laser in a microscope. The images are analyzed using chemometric based classification algorithms to determine whether the disease may become metastatic at some point in the future.

Scatterplots Showing Discrimination Between Gleason 7 Patients Who Progress and Those Who Do Not.

FALCON II™

• Features
• Specifications
• Applications
• FAQ's
• Image Gallery

• Application Notes
• Posters